Li Yan, M.D., Ph.D., Chief Medical Officer of Brii Biosciences, has the overall responsibility for clinical development, regulatory affairs, medical affairs, drug safety, IT and data sciences, quality assurance, and other related functions. As a founding member of the company, he is accountable for building the development team in US and China, strategizing portfolio, driving execution of clinical development programs and product registrations. He led the development, approval, and launch of first neutralizing antibody therapy against COVID-19 amubarvimab/romlusevimab in China. He is also responsible for communications with investors and successfully took the company IPO.
Prior to joining the company, Dr. Yan was Vice President and Head Unit Physician of GSK Oncology, where he oversaw global development of oncology assets focusing on immunotherapy, cancer epigenetics, and cell therapy. Prior to his tenure at GSK, he was Executive Director at Merck responsible for clinical development of oncology, respiratory and immunology, infectious diseases, and vaccines in emerging markets including the development of immunotherapy Keytruda (pembrolizumab) in China and other emerging markets countries. Dr. Yan started his industry career with Centocor, a Johnson & Johnson company, leading both discovery and clinical development of anti-cancer biologics.
Dr. Yan received his medical degree from Medical College of Peking University and a Ph.D. from the University of Kansas Medical Center. He completed his post-graduate training at Beijing Cancer Hospital, Peking University, and Boston Children’s Hospital, Harvard Medical School. He is an alumnus of the Harvard Business School enterprise executive program. Dr. Yan served adjunct professorships at Peking University and Yonsei University, and he is Managing Director of the US Chinese Anti-Cancer Association. He also serves in scientific committees of Chinese Anti-Cancer Association and Chinese Society for Clinical Oncology. He has published over 90 manuscripts and book chapters.